



eISSN 2279-7483

<https://www.pagepressjournals.org/index.php/vl/index>

**Publisher's disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

**Veins and Lymphatics** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

*All legal disclaimers applicable to the journal apply to this production process as well.*

Veins and Lymphatics 2025 [online ahead of print]

To cite this article:

Silvia Rossetto, Giulia Baldazzi, Alessandra Gallo, Paolo Zamboni. Mesotherapy *versus* oral medical treatment of chronic venous insufficiency in a general practitioner setting - A randomized controlled trial. *Veins and Lymphatics*. 2025;14:13189. doi:10.4081/vl.2025.13189

 ©The Author(s), 2025  
Licensee PAGEPress, Italy

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## Mesotherapy *versus* oral medical treatment of chronic venous insufficiency in a general practitioner setting - A randomized controlled trial

Silvia Rossetto,<sup>1</sup> Giulia Baldazzi,<sup>2</sup> Alessandra Gallo,<sup>3</sup> Paolo Zamboni<sup>4</sup>

<sup>1</sup>Medical Student, University of Ferrara;

<sup>2</sup>Department of Translational Medicine, School of Vascular Surgery, University of Ferrara;

<sup>3</sup>General Practitioner, Fossalta di Piave (VE);

<sup>4</sup>Professor and Chairman, Department of Translational Medicine, School of Vascular Surgery, University of Ferrara, Italy;

**Correspondence:** Giulia Baldazzi, School of Vascular Surgery, University of Ferrara, via A. Moro 8, 44124 Ferrara, Italy.

E-mail: giulia01.baldazzi@edu.unife.it

**Key words:** mesotherapy, chronic venous insufficiency, edema, varicose veins.

**Contributions:** SR, conceptualization, writing – original draft, data acquisition, interpretation and curation, and formal analysis; PZ, conceptualization, design of the work, review, supervision, and visualization; GB, writing – review and editing, supervision, and visualization; AG, conducting mesotherapy treatment. All the authors have read and approved the final version of the manuscript and agreed to be held accountable for all aspects of the work.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

**Conflict of interest:** the authors declare no potential conflict of interest.

**Funding:** none.

**Ethics approval and consent to participate:** this is a medical doctoral thesis approved by the Faculty of Medicine, Pharmacy, and Prevention of the University of Ferrara, Italy.

**Informed consent:** all patients treated with intradermal therapy signed the written informed consent approved by the Italian Society of Mesotherapy.

**Patient's consent for publication:** the patients gave their written consent to use their personal data for the publication of this paper and any accompanying images.

**Availability of data and materials:** all data generated or analyzed during this study are included in this published article.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## Abstract

Mesotherapy involves the introduction of drugs through dermal microinjections for preventive, therapeutic, or rehabilitative purposes. This study evaluates the safety, tolerability, and effectiveness of mesotherapy in treating Chronic Venous Insufficiency (CVI) compared to traditional oral treatments. Sixty-one patients with CVI (CEAP stage C3-C4) were randomized into two groups. The primary outcome was the measurement of bilateral ankle circumferences. Secondary outcomes included the evaluation of bilateral circumferences and subcutaneous ultrasound thicknesses at the thigh, calf, and medial ankle, and Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) stage variation. The treatment group (30 patients) received mesotherapy with a complex homeopathic product every 15 days for 3 months, and the control group (31 patients) was treated with oral flavonoids for 3 months. With no recorded adverse effects, mesotherapy led to significant reductions in bilateral ankle circumferences (right  $p=0.0008$ , left  $p=0.0075$ ), CEAP stage ( $p=0.0212$ ), ankle ultrasound thicknesses (right  $p=0.0037$ , left  $p=0.0015$ ) and calf thicknesses (right  $p=0.0131$ , left  $p=0.0137$ ). Mesotherapy was found to be safe, well tolerated, and more effective with respect to oral drugs in CVI patients; however, further randomized, controlled, and blind trials with wider sample sizes are mandatory to confirm our results.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## Introduction

Chronic Venous Insufficiency (CVI) is a pathological condition of an evolving nature characterized by morphological and functional abnormalities of the venous system,<sup>1</sup> resulting in a persistent and progressive reduction in the volume of fluid drainage from the periphery to the central level, leading to stagnation, dilation, and inflammation of the vein walls and surrounding tissues.<sup>2</sup>

From an epidemiological standpoint, it is a highly prevalent condition, with mild forms affecting up to 80%<sup>3</sup> of the global population. The female sex is more commonly affected, while men tend to have a higher percentage of complications, such as ulcers.<sup>4</sup> CVI is primarily found in industrialized countries and is associated with lifestyle factors, reduced physical activity, and widespread obesity.<sup>5</sup> A particularly significant finding from the RELIEF study<sup>6</sup> is that 78% of symptomatic patients are not treated, and only 45.9% of the population affected by CVI received a correct diagnosis from general practitioners, highlighting the need for significant public health education regarding this condition, which is too often underestimated or unrecognized.

In this context, mesotherapy, or District Intradermal Therapy (DIT), offers potential support. This technique, still relatively unknown and underutilized today, could prove to be a valid therapeutic alternative for patients with CVI, especially considering that an international committee has approved the recommendations for applying mesotherapy in pain medicine and aesthetic medicine, with over 100% consensus.<sup>7</sup>

Mesotherapy involves the introduction of drugs or substances into the dermis through microinjections in the specific lesion site to be treated. This creates a sort of “micro dermal depot” from which the substance diffuses very slowly into the underlying tissues via the hemolymphatic circulation. The active ingredient interacts almost exclusively with the local tissue receptors, exerting its biological

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

effect with minimal doses of the product, without the need to reach a threshold plasma concentration, as is required with oral administration.<sup>8,9</sup>

The side effects observed with mesotherapy are generally mild and consist of local reactions that resolve spontaneously in a short period. These include a small wheal at the injection site, along with erythema, induration, bruising, small hematomas, and mild pain. Potential adverse reactions reported in the literature include allergic reactions and skin infections resulting from inadequate hygiene during intradermal injection. These events are readily preventable through a thorough patient history and the maintenance of a sterile treatment environment.<sup>10-12</sup>

Unfortunately, the literature lacks studies comparing the treatment of CVI via mesotherapy with other pharmacological administration routes. Therefore, this study aims to assess whether the mesotherapeutic administration of phlebotonic drugs is safe, well-tolerated, and advantageous compared to standard oral treatment for the management of complicated venous insufficiency, using reproducible parameters as outcome indicators.

## **Materials and Methods**

A total of 61 patients were recruited from the General Medicine outpatient clinic in Fossalta di Piave (VE) during the period from April 8th, 2023, to January 29th, 2024. All patients were diagnosed with chronic venous insufficiency, confirmed by color Doppler ultrasound performed by public consultant specialists of the same geographical area. Only subjects with the clinical class C3 (edema) and C4 (skin pigmentation and lipodermatosclerosis), according to the Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification, were included in the study.<sup>2</sup>

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

The exclusion criteria considered for the study were: allergy to the injected substances or hypersensitivity to *Viscum album*, positive medical history of autoimmune diseases, presence of active tumors, current pregnancy or breastfeeding, previous treatments for chronic venous insufficiency (e.g., use of compression stockings, physiotherapy, or thermal therapies), patients undergoing treatment with anticoagulants, concomitant lymphedema, age below 18 years.

After agreeing to participate in the study, all patients underwent the collection of demographic data, physical examination for the assessment of clinical CEAP status, completion of the clinical evaluation form using the Venous Clinical Severity Score (VCSS), height measurement, weight measurement with a Bioelectrical Impedance Analysis (BIA) scale to obtain the Body Mass Index (BMI) value and determine the percentage of body fat and water, and circumference measurements at specific reference points on the lower limb: above the medial malleolus, posteriorly at the calf level, and at the thigh (Figure 1). Additionally, the thickness of edema in the subcutaneous tissues was measured via ultrasound evaluation at the same reference points (Figure 1), and the personal assessment form "The Short Form - 36" (SF-36) was completed.

After the initial evaluation (baseline), the patients were randomized into two arms through a computed system provided by the University of Ferrara through an author who was not involved in performing the trial and in data collection.

The "cases" underwent District Intra-dermal Therapy (DIT): the treatment protocol consisted of two sessions per month for 3 months, during which two milliliters of injectable vials of a complex multicomponent homeopathic product were administered, diluted with saline in a 1:1 ratio. The composition per vial is as follows: *Conium D3* 2.5 mg, *Hydrastis D3* 2.5 mg, *Viscum album D2* 2.5 mg, *Phytolacca D4* 2.0 mg, *Scilla D1* 2.0 mg, sodium chloride, water for injections.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

The possibility of injecting this homeopathic product via mesotherapy is specified in the product's leaflet<sup>13</sup> and approved by the Italian Society of Mesotherapy.<sup>7</sup> Moreover, the Italian Good Practice Clinical guidelines<sup>11</sup> indicate DIT as applicable to CVI. The contraindications for the use of this active ingredient in DIT include: a positive medical history of autoimmune diseases, neoplastic or paraneoplastic syndromes, a positive medical history of allergic diathesis to the drug or hypersensitivity to *Viscum album*, pregnancy, breastfeeding, and patients undergoing treatment with anticoagulants. Drug interactions remain unknown.<sup>10,12-19</sup> All individuals presenting any of these conditions were excluded from the study.

The mesotherapy technique specifically involves drug infiltration with a disposable syringe at a 30-degree angle to reach a depth of 2 mm (corresponding to the dermal layer, which ranges from 1.5 to 3 mm). Micro-injections are performed approximately 2 cm apart from each other.<sup>8,10</sup>

Before undergoing DIT, all patients signed informed consent.

The "controls" received oral phlebotonic treatment, primarily consisting of diosmin and hesperidin, at a dosage of 1 and 2 tablets daily, respectively, for a duration of three months.

At the end of the 3 months, the patients were re-evaluated using the same methods as during the post-recruitment visit.

The primary outcome of the trial was the measurement of bilateral ankle circumferences. The secondary outcomes of the study included the measurement of bilateral circumferences (in centimeters, cm) and the evaluation of the subcutaneous thicknesses, assessed via ultrasound at the thigh, calf, and medial ankle (cm), respectively, points F, D, and B used for elastic stockings measurements. Moreover, the eventual change in the CEAP stage, the safety of the treatment (evaluated by the number of adverse reactions related to both treatments during the three-month

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

treatment cycle), the Venous Clinical Severity Score, and the eight items of the subjective evaluation from Short Form-36 were analyzed as secondary outcomes. Additional outcome indicators included gender, age, Body Mass Index (BMI, kg/m<sup>2</sup>), fat percentage (%), and water percentage (%).

### ***Statistical analysis***

Categorical variables were expressed as absolute (N) or relative (%) values, while continuous variables were expressed as mean  $\pm$  Standard Deviation (SD). Non-parametric data were statistically processed using the Wilcoxon test. A p-value  $<0.05$  was considered statistically significant.

### **Results**

Sixty-one patients, aged between 18 and 89 years, affected by CVI at CEAP stages C3-C4, were included and randomized into the two study groups (cases N=30 and controls N=31). The two groups were homogeneous in terms of age [58.73 $\pm$ 5.34 years in the case group and 59.77 $\pm$ 14.97 years in the control group (p=0.7896)] and gender (3 males and 27 females in the case group, 3 males and 28 in the control group]. The two populations were homogeneous at baseline for all clinical and subjective well-being parameters evaluated, as shown in Figure 2. At the end of the treatment, 59 patients were re-evaluated with the same baseline tests, as two subjects withdrew from the study (1 from the case group and 1 from the control group).

The primary outcome analysis showed significant reductions in the bilateral circumferences measured at the B point in the DIT group compared to the control arm (right p=0.0008, left p=0.0075). Among the secondary outcomes, in the “case” group, there were consistently significant reductions in ultrasound-assessed thicknesses at the medial malleolus (right p=0.0037, left p=0.0015) and at the

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

calf (right  $p=0.0131$ , left  $p=0.0137$ ). Additionally, in the DIT group, there was a subjective decrease in physical limitations due to CVI compared to the controls ( $p=0.0181$ ), and a significant change in the clinical CEAP ( $p\text{-value}=0.0212$ ). Furthermore, no major adverse events related to mesotherapy were recorded throughout the entire follow-up. Only mild side effects were observed in the DIT group: one patient reported mild pain during needle insertion, one patient experienced transient erythema, which resolved spontaneously within a few hours at most, and in 11 patients, an ecchymosis developed at the injection site, which resolved in approximately one week. In the control group, there was one participant who had a mild feeling of nausea and one who reported weakness. Additional details on the results from these measurements and the administration of study tests are shown in Figure 3.

## Discussion

The results of the study highlighted that the mesotherapy treatment was both safe and well-tolerated. In fact, with systemic treatment, it is necessary to maintain high plasma doses to ensure constant drug action, thus requiring more frequent administrations compared to local injections.<sup>9</sup> It has been highlighted that intradermal administration of the same drug achieves a more constant and prolonged tissue kinetic curve.<sup>10</sup>

Furthermore, oral administration requires the drug to be systemically circulated, necessitating a much greater metabolic action than local infiltration, resulting in minimal passage into the general circulation. This is particularly relevant in patients with comorbidities, such as reduced hepatic biotransformation efficiency (chronic liver disease) or impaired renal excretory function (kidney

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

failure), which can lead to alterations in the drug concentration reaching the site of action or an extended presence of the drug in the systemic circulation, increasing the risk of toxic effects.

Mesotherapy employs minimal drug doses sufficient to achieve the therapeutic effect swiftly, thereby reducing the risk of iatrogenic adverse events and preventing potential organ toxicity. This "drug-sparing" effect is particularly significant in patients undergoing polytherapy, who are already taking multiple pharmaceutical agents systemically, with the possibility of chemical-physical interactions both in the bloodstream and at the site of action, which may compromise the bioavailability and efficacy of the treatments.<sup>8</sup>

Moreover, DIT can be combined with other techniques, leveraging multimodal therapeutic synergy by associating two approaches with different modes of action (pharmacological or non-pharmacological), allowing further dose-sparing and shorter recovery times.<sup>8,11</sup>

Additionally, mesotherapy proved to be effective, as the therapeutic response to this treatment was significantly better compared to the oral route.

It can be assumed that the reduction in circumferences, particularly at the distal level of the lower limbs, is associated with better tissue edema reabsorption in the mesotherapy group, as the ultrasound-measured subfascial thicknesses were significantly reduced in the same areas where a significant reduction in circumferences was observed. Therefore, it's not surprising that the reduction in edema, which is the most prominent manifestation of the chronic inflammation caused by the disease, led to a reduction in the CEAP clinical stage in 5 cases and 0 controls, along with a decrease in the Venous Clinical Severity Score (VCSS) values.<sup>14-17</sup>

The DIT performed involved initial local injections at the medial malleolus, which is the area most affected by increased hydrostatic pressure in CVI, followed by infiltrations in the leg and thigh.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

Therefore, the greater significance obtained in this region may be attributed to the larger amount of drug injected in that specific area (Figure 4). Furthermore, upon reassessing body weight at the third month of treatment, it was observed that weight did not always decrease, but instead remained stable or slightly increased in both the case group (DIT) and the control group (oral phlebotonics), as shown in Tables 1 and 2.

This supports the interpretation that the observed results might be due to an improvement in the venous circulation and that the decrease in measurements is reasonably attributed to the reduction of edema rather than fat mass. In fact, extracellular fluid is elevated in CVI due to fluid stagnation in the lower limbs, and mesotherapy aims to reduce it through local injections of the homeopathic product. This substance has a positive effect on the lymphatic system as it improves the system's ability to remove excess filtrate from the capillaries in the interstitial space and accelerates the drainage of toxins, causing inflammation. This mechanism may contribute to the reduction of edema.<sup>18,19</sup> Supporting this, ultrasound imaging demonstrated a reduction in subcutaneous layer thickness, which contains extracellular water (Figure 5).

Furthermore, post-treatment Bioimpedance Analysis (BIA) revealed an increase in Total Body Water (TBW): as Fat Mass (FM) decreased, Fat-Free Mass (FFM) increased, leading to a corresponding rise in TBW, as FFM contains a higher proportion of water than adipose tissue.<sup>20</sup> Since BIA can be influenced by external factors and the patient's health status, prior to the measurement, patients were provided with specific instructions on how to prepare for the examination.

However, the subjective experience of the patient and their perception of the disease itself must not be overlooked. Thus, this study included the SF-36 questionnaire, which documented an improvement in the patient's perceived general health after the treatment for CVI, with a statistically significant

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

difference only in physical limitations due to pain. Recent studies<sup>21,22</sup> suggest that the effectiveness of mesotherapy is not only due to the local pharmacological action but also to the technique used (intra-dermal injection): the needle stimulates a reflex analgesic action, while the osmotic action and the increased pressure in the tissues, due to the deposited solution, lead to the activation of A-delta and C afferent fibers, resulting in the activation of the "gate control" mechanism, which modulates pain<sup>11</sup>. Thus, while mesotherapy is already considered a valid and relevant technique, as denoted by experts' consensus,<sup>6,8,10,11,23</sup> and recommended in various fields such as pain management, rehabilitation, dermatology, aesthetics, and immune prophylaxis, there remain open questions regarding the standardization of methodology, treatment protocols, drug dosages, estimation of actual therapy success rates, and potential combination with other treatments. In current literature, no other studies have evaluated the efficacy of DIT in CVI by comparing it with a control group treated solely with oral therapy, both from a clinical perspective and by assessing more objective parameters (although not entirely objective) such as ultrasound evaluation of subcutaneous tissue thickness, lower limb circumferences, and Bioimpedance Analysis (BIA), which represents one of the study's main limitations. Another limitation of this study is the small sample size, but the data collected might provide a solid foundation for further research on this topic.

## Conclusions

The main shortcoming of our study is the competitor of mesotherapy, which is represented by the less powerful available therapy for CVI, *i.e.* the medical treatment. Surgery, compression, sclerotherapy are certainly the most effective treatments for CVI,<sup>24-26</sup> and the most recommended in Guidelines.<sup>27</sup> There is no discussion about such a statement, and the authors do not want to push mesotherapy as a

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

more powerful therapy. However, in the general practitioner setting, there are frequently patients who refuse surgery or even sclerotherapy and/or have scarce compliance to compression, albeit proposed by specialists. In these cases, the family doctor prescribes phlebotonic drugs, and our findings now support to prefer the intradermal route of administration because safe and more effective.

Moreover, a second limitation of this trial might be considered the use of a homeopathic drug in the treatment arm. The lack of injectable phlebotonic drugs on the market led the researchers to use an injectable product without any specific validated medical indications, but with scientific articles supporting possible therapeutical effects in CVI.<sup>27-29</sup>

The encouraging results of this study could, therefore, allow for the calculation of the sample size necessary for conducting further randomized, controlled, placebo-blind clinical trials, opening a new frontier in the treatment of a widespread condition like CVI. This technique of drug administration could potentially be aimed to become a complementary or adjuvant treatment for CVI, especially for patients refusing invasive treatments and/or compression in case of edema and lipodermatosclerosis.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## References

1. Lee BB, Nicolaides AN, Myers K, et al. Venous hemodynamic changes in lower limb venous disease: the UIP consensus according to scientific evidence. *Int Angiol* 2016;35:236-52.
2. Zamboni P, Traina L, Giancesini S. In: Dionigi R, Dionigi Chirurgia. Settima edizione. Edra, Perignano, Italy, 2023.
3. Apollonio A. In: Frullini A, Manuale di flebologia ambulatoriale. Officina Editoriale Oltrarno, Firenze, Italy, 2023.
4. White JV, Ryjewski C. Chronic venous insufficiency. *Perspect Vasc Surg Endovasc Ther* 2005;17:319-27.
5. Azar J, Rao A, Oropallo A. Chronic venous insufficiency: a comprehensive review of management. *J Wound Care* 2022;31:510-9.
6. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized Flavonoids. *Angiology* 2002;53:245-56.
7. Mammucari M, Vellucci R, Mediati D, et al. What is mesotherapy? Recommendations from an international consensus. *Trend in Medicine* 2014;14:1-10.
8. Mammucari M, Maggiori E, Cresta P, et al. Trattato di intradermo terapia distrettuale. EMSI, Roma, Italy, 2022.
9. Mammucari M, Maggiori E, Lazzari M, et al. Should the general practitioner consider mesotherapy (intradermal therapy) to manage localized pain? *Pain Ther* 2016;5:123-6.
10. Maggiori S. L'intradermoterapia distrettuale. La mesoterapia in Italia. EMSI, Roma, Italy, 2013.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

11. + Mammucari M, Mercandante S. Norme di buona pratica clinica in mesoterapia. EMSI, Roma, Italy, 2022.
12. Mammucari M, Russo D, Maggiori E, et al. Evidence-based recommendations on mesotherapy: an update from the Italian Society of Mesotherapy. Clin Ter 2021;171:e37-45.
13. PASCOE Lyndiaral. Injectable vials, package leaflet.
14. Zamboni P, Lanzara S, Mascoli F, et al. Inflammation in venous disease. International Angiology 2008;27:361-9.
15. Rizzi A, Quaglio D, Zamboni P, et al. Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg 1998;28:855-61.
16. Zamboni P, Tisato V, Menegatti E, et al. Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. Cytokine 2013;63:92-6.
17. Ligi D, Croce L, Mannello F. Inflammation and compression: the state of art. Veins and Lymphatics 2016;5:5980.
18. Albergati F, Farina M, Bacci PA. Valutazione dell'attività di Lyndiaral sull'omeostasi endoteliale nella stasi circolatoria: studio clinico pilota in doppio cieco, randomizzato, controllato con placebo ed in cross-over. Campisi C, Zilli A, Eretta C. Efficacia di Lyndiaral nel trattamento del linfedema cronico degli arti: studio caso controllo. Linfologia Italiana 2004
19. Maggiori E., Bartoletti E., Mammucari M. Intradermal therapy (mesotherapy) with lyndiaral in chronic venous insufficiency and associated fibrosclerotic edema damage: a pilot study. J Altern Complement Med 2013;19:777-81.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

20. Davids MR, Edoute Y, Jungas RL, et al. Facilitating an understanding of integrative physiology: emphasis on the composition of body fluid compartments. *Can J Physiol Pharmacol* 2002;80:835-50.
21. Viscido R, Ferrara PE, Ljoka C, et al. Mesotherapy as a treatment of pain and disability in patients affected by neck pain in spondylartrosis. *Ig Sanita Pubbl* 2018;74:95-101.
22. Ferrara PE, Ronconi G, Viscito R, et al. Efficacy of mesotherapy using drugs versus normal saline solution in chronic spinal pain: a retrospective study. *Int J Rehabil Res* 2017;40:171-4.
23. Paolucci T, Russo D, Maggiori E, et al. A call to action by the Italian Mesotherapy Society on Scientific Research. *Drug Des Devel Ther* 2021;15:3041-7.
24. Pavei P, Ferrini M, Spreafico G, et al. Ultrasound guided foam sclerotherapy of recurrent varices of the great and small saphenous vein: 5-year follow up *Veins and Lymphatics* 2014;3:4655.
25. Ricci S. The sapheno femoral junction involvement in the treatment of varicose veins disease *Veins and Lymphatics* 2017;6:6822.
26. Tessari M, Menegatti E, Zamboni P, et al. Elastic stockings effect on leg volume variability in healthy workers under prolonged gravitational gradient exposure *Veins and Lymphatics* 2015;4:5182.
27. De Maeseneer MG, Kakkos SK, Aherne T, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. *Eur J Vasc Endovasc Surg* 2022;63:184-267.
28. Palmieri. **Trattamento dell'edema flebolinfatico con Lyndiaral. In: *Medicina Funzionale*, 2011.**

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

29. Gasbarro V, Cataldi A, Poverini R, et al. Modificazioni morfologiche dei linfonodi in corso di trattamento con Lyndiaral. Trattamento topico e mesoterapico con Lyndiaral in pazienti affetti da PEFS 3-2011. In: Medicina Funzionale, 2011.


30. Sukhareva M, Egorova O, Belov B. Lipodermatosclerosis as a type of lobular panniculitis: the effectiveness of non-pharmacological treatment methods. Annals of the Rheumatic Diseases 2020;79:1821.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

**Figure 1.** Reference points: A) above the medial malleolus; B) posteriorly below the knee; C) posteriorly on the thigh.



*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

**Figure 2.** Evaluations of demographic, clinical parameters and questionnaires administered to patients in the two study groups at baseline.

Age	Pvalue	Stage	Pvalue	BMI (kg/m <sup>2</sup> )	Pvalue	Fat (%)	Pvalue	Water (%)	Pvalue	CircAdx (cm)	Pvalue	
Baseline	58,73 ±	3,30 ±	27,7 ±	34,2 ±	48,77 ±	27,46 ±						
cases	5,34	0,46	5,18	6,78	3,09	2,49						
Baseline	59,77 ±	3,41 ±	30,60 ±	36,70 ±	46,63 ±	27,45 ±						
controls	14,97	0,7896	0,50	6,63	0,0713	9,24	0,2248	5,02	0,0507	2,57	0,9816	
CircBdx (cm)	Pvalue	CircCdx (cm)	Pvalue	CircAsx (cm)	Pvalue	CircBsx (cm)	Pvalue	CircCsx (cm)	Pvalue	Thickness Adx (cm)	Pvalue	
Baseline	39 ±	57 ±	27,6 ±	38,96 ±	56,6 ±	1,03 ±						
cases	3,95	6,38	2,71	4,08	6,29	0,30						
Baseline	39,19 ±	57,03 ±	27,19 ±	39,12 ±	57,16 ±	0,98 ±						
controls	4,02	0,8504	6,18	0,9841	2,62	0,5543	4,03	0,8766	6,39	0,7311	0,40	0,5869
Thickness Bdx (cm)	Pvalue	Thickness Cdx (cm)	Pvalue	Thickness Asx (cm)	Pvalue	Thickness Bsx (cm)	Pvalue	Thickness Csx (cm)	Pvalue	VCSS	Pvalue	
Baseline	1,19 ±	1,48 ±	0,94 ±	1,10 ±	1,40 ±	11,1 ±						
cases	0,30	0,34	0,25	0,27	0,46	3,16						
Baseline	1,10 ±	1,36 ±	0,97 ±	1,05 ±	1,29 ±	11,51 ±						
controls	0,29	0,2599	0,54	0,2834	0,35	0,6606	0,28	0,5043	0,51	0,4018	3,33	0,6243

authors.

The publis  
Any queri

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

	Physical functioning	Pvalue	Physical imitations	Pvalue	Emotional limitations	Pvalue	Energy/fatigue	Pvalue
Baseline cases	2,63 ± 0,32		1,45 ± 0,27		1,61 ± 0,30		4,04 ± 0,32	
Baseline controls	2,7 ± 0,27	0,4095	1,42 ± 0,22	0,7260	1,72 ± 0,30	0,1599	4,15 ± 0,34	0,1977
	Emotional well-being	Pvalue	Social activities	Pvalue	Pain	Pvalue	Perception of general health	Pvalue
Baseline cases	4,46 ± 0,24		2,83 ± 0,33		2,76 ± 0,50		2,88 ± 0,35	
Baseline controls	4,53 ± 0,27	0,3050	2,83 ± 0,27	0,9447	2,56 ± 0,62	0,1721	2,85 ± 0,30	0,6823

plied by the authors.  
t those of their  
s not guaranteed or

The publisher is not resp  
Any queries should be di  
All claims expressed in t  
affiliated organizations,  
Any product that may be  
endorsed by the publishe

**Figure 3.** Re-evaluation at 3 months from the start of treatment, in both study groups, of the clinical, ultrasound parameters, and administered questionnaires.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

Stage	P-value	BMI (kg/m <sup>2</sup> )	P-value	Fat (%)	P-value	Water (%)	P-value	CircAdx (cm)	P-value	CircBdx (cm)	P-value
<b>Casi after</b>											
<b>3 months</b>	3.13 ± 0.35	27.66 ± 5.42	32.49 ±	48.96 ± 3.6	24.75 ±	37.44 ± 4.4					
	<b>0,0212*</b>	0,0559	7.16	0,0506	0,2922	2.23	<b>0,0008*</b>	0,1257			
<b>Controls</b>											
<b>after 3 months</b>	3.40 ± 0.49	30.71 ± 6.7	36.91 ±	47.69 ±	26.93 ±	39.13 ± 4.08					
			9.88	5.53	2.53						
<b>Cases</b>											
<b>after 3 months</b>	55.52 ±	25.31	37.66 ±	55.31	0.68 ± 0.27	0.81 ± 0.30					
	6.72	± 2.38	4.43	± 6.42							
	0.4141		<b>0,0075*</b>	0.1839	0.2927	<b>0,0037*</b>	<b>0,0131*</b>				
<b>Controls</b>											
<b>after 3 months</b>	56.90 ±	26.97 ±	39.13 ±	57.06 ±	0.91 ± 0.32	1.01 ± 0.31					
	6.40	2.43	4.15	6.50							
<b>Thickness</b>											
<b>P-value</b>											
<b>Thickness</b>											
<b>P-value</b>											
<b>Cdx (cm)</b>											
<b>Asx (cm)</b>											
<b>Bsx (cm)</b>											
<b>Csx (cm)</b>											
<b>VCSS</b>											
<b>P-value</b>											
<b>Cases</b>											
<b>after 3 months</b>	1.08 ± 0.37	0.66 ± 0.25	0.80 ± 0.29	1.08 ± 0.37	9.79 ± 3.14						
	0.2110	0.0015*	0.0137*	0.1461	0.0790						
<b>Controls</b>											
<b>after 3 months</b>	0.90 ± 0.31	1 ± 0.31	1.25 ± 0.53	11.27 ±	3.29						
	1.21 ± 0.47										

The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

	Physical functioning	Pvalue	Physical limitations	Pvalue	Emotional limitations	Pvalue	Energy/fatigue	Pvalue
<b>Cases after 3 months</b>	2,76 ± 0,27		1,63 ± 0,27		1,73 ± 0,27		4,05 ± 0,31	
<b>Controls after 3 months</b>	2,73 ± 0,27	0,6340	1,46 ± 0,26	0,0181*	1,70 ± 0,31	0,7618	4,13 ± 0,33	0,3387
	<b>Emotional well-being</b>	<b>Pvalue</b>	<b>Social activities</b>	<b>Pvalue</b>	<b>Pain</b>	<b>Pvalue</b>	<b>Perception of general health</b>	<b>Pvalue</b>
<b>Cases after 3 months</b>	4,64 ± 0,26		2,84 ± 0,38		2,37 ± 0,41		2,98 ± 0,41	
<b>Controls after 3 months</b>	4,56 ± 0,30	0,2714	2,85 ± 0,26	0,9519	2,50 ± 0,66	0,4107	2,88 ± 0,35	0,3204

The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.


Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

**Figure 4.** A) and C) represent lower limbs before mesotherapy, B) and D) represent them after mesotherapy.




*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

**Figure 5.** A) edema thickness before mesotherapy and B) post mesotherapy; C) edema thickness before oral treatment and D) post oral treatment.



*The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.*

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.*

*Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*